New combo therapy may help more liver cancer patients qualify for transplant

This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y-90) can shrink liver tumors enough for patients to become eligible for a liver transplant. About 40 adults with hepatocellular carcinoma (HCC) will receive this combination before transplant. The goal is to see if the treatment helps control the disease and improves chances of getting a transplant.